TJ0711, a novel vasodilatory β-blocker, protects SHR rats against hypertension induced renal injury

American Journal of Translational Research

Volumn 5, Issue 3, 2013, Pages 279-290

  Yang, Juan ^a   Ning, Yong ^a   Qiu, Jun ^a   He, Jin Seng ^a   Li, Wei ^a   Ma, Zu Fu ^a   Shao, Ju Fang ^a   Yue Qiang, L I ^a   Zeng, Rui ^a   Zhang, Meng ^a   Cheng, Jia ^a   Chen, Su Fang ^a   Xu, Gang ^a   Wang, Cong Yi ^a,b   Yao, Ying ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Carvedilol; Hypertension; Renal injury; Renoprotection; TJ0711

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TJ 0711; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; KIDNEY PERFUSION; MALE; MICROSCOPY; NONHUMAN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

RATTUS;

EID: 84877080315     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT and Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-1757.
2. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD and Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996; 17 Suppl B: 8-16.
3. Hart PD and Bakris GL. Should beta-blockers be used to control hypertension in people with chronic kidney disease? Semin Nephrol 2007; 27: 555-564.
4. Sun S, Si L, Fan Z, Qiu J and Li G. Stereoselective HPLC assay of TJ0711 enantiomers by precolumn derivatization with GITC using UV detection and its application in pharmacokinetics in rats. J Huazhong Univ Sci Technolog Med Sci 2009; 29: 427-430.
5. Zhang S, Lv JW, Yang P, Yu Q, Pang J, Wang Z, Guo H, Liu S, Hu J, Li J, Leng J, Huang Y, Ye Z and Wang CY. Loss of dicer exacerbates cyclophosphamide-induced bladder overactivity by enhancing purinergic signaling. Am J Pathol 2012; 181: 937-946.
6. Rao X, Zhong J, Zhang S, Zhang Y, Yu Q, Yang P, Wang MH, Fulton DJ, Shi H, Dong Z, Wang D and Wang CY. Loss of methyl-CpG-binding domain protein 2 enhances endothelial angiogenesis and protects mice against hind-limb ischemic injury. Circulation 2011; 123: 2964-2974.
7. Zhong J, Yang P, Muta K, Dong R, Marrero M, Gong F and Wang CY. Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock. PLoS One 2010; 5: e9593.
8. Miao Z, Yan S, Wang J, Wang B, Li Y, Xing X, Yuan Y, Meng D, Wang L, Gu J, Zhang S, Li C and Wang CY. Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions. Inflamm Res 2009; 58: 659-668.
9. Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C and Mantzoros CS. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003; 88: 4823-4831.
10. Savard S, Lavoie P, Villeneuve C, Agharazii M, Lebel M and Lariviere R. eNOS gene delivery prevents hypertension and reduces renal failure and injury in rats with reduced renal mass. Nephrol Dial Transplant 2012; 27: 2182-2190.
11. Zemse SM, Chiao CW, Hilgers RH and Webb RC. Interleukin-10 inhibits the in vivo and in vitro adverse effects of TNF-alpha on the endothelium of murine aorta. Am J Physiol Heart Circ Physiol 2010; 299: H1160-1167.
12. Lin H, Yu CH, Jen CY, Cheng CF, Chou Y, Chang CC and Juan SH. Adiponectin-mediated heme oxygenase-1 induction protects against ironinduced liver injury via a PPARalpha dependent mechanism. Am J Pathol 2010; 177: 1697-1709.
13. Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL and Choi AM. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 1997; 272: 5375-5381.
14. Kozako T, Matsumoto N, Kuramoto Y, Sakata A, Motonagare R, Aikawa A, Imoto M, Toda A, Honda S, Shimeno H and Soeda S. Vasohibin induces prolyl hydroxylase-mediated degradation of hypoxia-inducible factor-1alpha in human umbilical vein endothelial cells. FEBS Lett 2012; 586: 1067-1072.
15. Ritz E and Rump LC. Do beta-blockers combined with RAS inhibitors make sense after all to protect against renal injury? Curr Hypertens Rep 2007; 9: 409-414.
16. Jovanovic D, Jovovic D, Mihailovic-Stanojevic N, Miloradovic Z, Naumovic R, Dimitrijevic J, Maksic N and Djukanovic L. Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy. Biomed Pharmacother 2009; 63: 571-576.
17. Rodrigues MA, Rodrigues JL, Martins NM, Barbosa F, Curti C, Santos NA and Santos AC. Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria. Chem Biol Interact 2011; 189: 45-51.
18. Carvalho Rodrigues MA, Gobe G, Santos NA and Santos AC. Carvedilol protects against apoptotic cell death induced by cisplatin in renal tubular epithelial cells. J Toxicol Environ Health A 2012; 75: 981-990.
19. Singh D, Chander V and Chopra K. Carvedilol attenuates ischemia-reperfusion-induced oxidative renal injury in rats. Fundam Clin Pharmacol 2004; 18: 627-634.
20. Groszek G, Nowak-Krol A, Wdowik T, Swierczynski D, Bednarski M, Otto M, Walczak M and Filipek B. Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxy phenoxy) ethylamino)propan-2-ol analogs and its enantiomers. Part 2. Eur J Med Chem 2009; 44: 5103-5111.
21. Chiu CC, Lin YT, Tsai CH, Liang JC, Chiang LC, Wu JR, Chen IJ and Yeh JL. Pharmacological effects of an aldehyde type alpha/beta-adrenoceptor blocking agent with vasodilating properties. Gen Pharmacol 2000; 34: 391-400.
22. Takara K, Sakaeda T and Okumura K. Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance. Anticancer Drugs 2004; 15: 303-309.
23. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A and Weyand CM. Inflammation, immunity, and hypertension. Hypertension 2011; 57: 132-140.
24. Vianna HR, Soares CM, Tavares MS, Teixeira MM and Silva AC. [Inflammation in chronic kidney disease: the role of cytokines]. J Bras Nefrol 2011; 33: 351-364.
25. Miyamoto T, Carrero JJ and Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 662-668.
26. Kaminski A, Pohl CB, Sponholz C, Ma N, Stamm C, Vollmar B and Steinhoff G. Up-regulation of endothelial nitric oxide synthase inhibits pulmonary leukocyte migration following lung ischemia-reperfusion in mice. Am J Pathol 2004; 164: 2241-2249.
27. Park JW, Chun YS and Kim MS. Hypoxia-inducible factor 1-related diseases and prospective therapeutic tools. J Pharmacol Sci 2004; 94: 221-232.
28. Tanaka T and Nangaku M. Drug discovery for overcoming chronic kidney disease (CKD): prolyl-hydroxylase inhibitors to activate hypoxiainducible factor (HIF) as a novel therapeutic approach in CKD. J Pharmacol Sci 2009; 109: 24-31.
29. Katavetin P, Inagi R, Miyata T, Tanaka T, Sassa R, Ingelfinger JR, Fujita T and Nangaku M. Albumin suppresses vascular endothelial growth factor via alteration of hypoxia-inducible factor/hypoxia-responsive element pathway. Biochem Biophys Res Commun 2008; 367: 305-310.
30. Sato Y and Sonoda H. The vasohibin family: a negative regulatory system of angiogenesis genetically programmed in endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27: 37-41.
31. Dandona P, Ghanim H and Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007; 25: 731-741.
32. Calo LA, Semplicini A and Davis PA. Antioxidant and antiinflammatory effect of carvedilol in mononuclear cells of hypertensive patients. Am J Med 2005; 118: 201-202.